Page 85 - NobleCon19revC2_Neat

Eledon Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS ELDN

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (10.04) (11.11) (10.35) (11.20) (42.70)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (58.38) (10.77) (9.58) (10.35) (89.08)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 92.79 82.31 106.79 96.07 96.07
Cash & Short Term Investments 56.41 46.49 40.95 3.67 3.67
% of Assets 61% 56% 38% 4% 4%
Current Assets -Total 59.52 48.90 73.62 62.99 62.99
% of Assets 64% 59% 69% 66% 66%
Total Liabilities 8.61 7.51 6.84 4.73 4.73
% of Assets 9% 9% 6% 5% 5%
Current Liabilities - Total 6.48 5.48 4.90 2.90 2.90
% of Assets 7% 7% 5% 3% 3%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 84.18 74.79 99.95 91.34 91.34
% of Assets 91% 91% 94% 95% 95%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (9.48) (9.92) (8.22) (12.25) (39.88)
Net Cash Flow - Investing NA NA (30.33) (25.03) (55.36)
Net Cash Flow - Financing NA NA 33.02 0.00 33.02

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference